GIA
BBNX

Gladstone Institutional Advisory’s Beta Bionics BBNX Stock Holding History

Gladstone Institutional Advisory’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$142K Hold
14,200
– – 0.01% 811
2025
Q4 		$433K Hold
14,200
– – 0.02% 529
2025
Q3 		$282K Hold
14,200
– – 0.01% 667
2025
Q2 		$207K Buy
+14,200
New +$201K 0.01% 709

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Gladstone Institutional Advisory's BBNX Position: Q1 2026 in Review

Gladstone Institutional Advisory held its Beta Bionics (BBNX) position steady in Q1 2026 at 14,200 shares worth $142K. The position accounts for 0.01% of the portfolio, ranked #811.

Gladstone Institutional Advisory first reported a position in BBNX in Q2 2025 and has held it in 4 quarters since. The position peaked at $433K in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Gladstone Institutional Advisory held 14,200 shares of Beta Bionics worth $142K as of Q1 2026.
  • Gladstone Institutional Advisory left its Beta Bionics share count unchanged in Q1 2026.
  • Beta Bionics made up 0.01% of Gladstone Institutional Advisory's portfolio in Q1 2026, its #811 holding.
  • Gladstone Institutional Advisory first reported a position in Beta Bionics in Q2 2025 and has held it in 4 quarters since.
  • Gladstone Institutional Advisory's Beta Bionics position peaked at $433K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Gladstone Institutional Advisory's 13F filing for Q1 2026, filed 14 May 2026.